O180 SAFETY AND IMMUNOGENICITY OF THE HPV-16/18 AS04-ADJUVANTED VACCINE IN HIV-POSITIVE WOMEN IN SOUTH AFRICA UP TO 12 MONTHS AFTER VACCINATION